NICE backs wider tumour profiling use in early breast cancer
Three tests that can be used to profile tumours in people with breast cancer and predict whether they will respond to chemotherapy have been cleared for wider use by the N
Newsletters and Deep Dive digital magazine
Three tests that can be used to profile tumours in people with breast cancer and predict whether they will respond to chemotherapy have been cleared for wider use by the N
Pfizer will draw on the expertise of Citi analyst Andrew Baum when it comes to portfolio management and capital deployment, naming him chief strategy and innovation office
Novartis has struck another deal to strengthen its position in radiopharmaceuticals, agreeing to pay $1 billion upfront for radioligand therapy (RLT) developer Mariana Onc
A personalised vaccine for the aggressive and fatal brain cancer glioblastoma has shown encouraging signs of efficacy in its first human trial.
Astellas has clearly been impressed with a partnership signed last August with Poseida Therapeutics on the development of cell therapies for solid tumours, as it has just
Editor's Picks
Newsletters and Deep Dive
digital magazine